http://www.stemcellbiotherapy.com
Stem Cell Biotherapy is dedicated to providing comprehensive, safe and ethical access to Stem Cell Therapy. Individuals suffering from disabling and life threatening illnesses have turned to Stem Cell Therapy where traditional medicine has not provided answers or traditional treatments have failed. We have collaborated with some of the world's most reputable and reliable bio-tech companies to provide access to the therapeutic applications of Cord Blood Stem Cell Therapy. Please complete and submit the following form: Address & Phone
The PACT Group provides education, leadership and production assistance to the cell therapy community through contract manufacturing of therapeutic cell products. Make your clinical funds go further, leave the manufacturing to us. PACT is an NHLBI-funded contract manufacturing program aimed at helping investigators develop novel somatic cell therapy products. Our Facilities for Your Product. Our Expertise on Your Team. Partners in the Development of Cell Therapies. PACT's three GTP/GMP manufacturing facilities and experienced personnel provide assistance in areas ranging from the translational development to the scale up of cell therapy products intended for use in human clinical trials.
Founded in 1995, Medra is a pioneer in stem cells and the leading provider of Fetal Stem Cell Therapy. Medra has already delivered the promise of Fetal Stem Cells to over one thousand patients, both children and adults. Medra also treats patients for general wellness and longevity. Medra was founded and is lead by Dr. William Rader, who serves as Medra's medical director and chief scientist and has worked with Fetal Stem Cells for over 12 years. Medra has offices and laboratories in California U.S.A., Georgia (The Former Soviet Republic), Germany and the Dominican Republic.
ZelleRx Corporation is a biopharmaceutical company developing cancer treatment products based on its proprietary natural killer (NK) cell line, NK-92. The company has a pipeline of universal and targeted products in clinical development against a variety of cancers as adjuvant and primary therapies.
http://www.vestatherapeutics.com
Vesta has made significant progress in developing proprietary methods of isolating, characterizing and manufacturing human hepatocytes directly from liver tissue, and these hepatocytes have been accepted by the FDA for use in early stage clinical trials. The Company is also developing methods to expand and differentiate hepatic progenitor cells. Vesta's approach is to use its technical strengths, patented intellectual property and know how in all stages of cell-based therapy to perfect and develop technologies to produce hepatocytes for therapeutic use. This approach can be summarized as the following three goals:Vesta will continue to optimize methods of expanding mature liver cells. Vesta will leverage its emerging proprietary strengths in hepatocyte progenitor cell isolation to conduct optimization studies on the expansion, differentiation and storage of these progenitor cells. Compared to mature hepatocytes, these cells have more extensive proliferative capacity, potentially expanding the use of a single donor organ to treat many patients. Vesta will examine the immunogenicity of expanded cells - mature hepatocytes and hepatocyte progenitor cells. With success in early clinical trials of mature hepatocytes and/or hepatocyte progenitor cells, the Company will seek one or more partners to take the products through late stage clinical development and into commercialization.
Incorporated in 2005 and headquartered in Hackensack, New Jersey, Amorcyte, Inc. is a development stage cellular therapies company focused on developing cell therapeutics for cardiovascular disease. Our lead product, AMR-001 is an autologous stem cell product for the treatment of damaged heart muscle following acute myocardial infarction (AMI). Amorcyte is a company with a corporate structure that is designed to minimize costs, maximize return on investment, and minimize the risks of product and corporate development, while maximizing the potential for speedy product approval.
Odontis is developing a biological replacement tooth product , the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development.
Protide Pharmaceuticals, Inc. is a fully integrated organization devoted to the discovery, development and commercialization of technologies and processes in clinical cell therapy, transfusion medicine, cell engineering and transplantation. Celox Laboratories is an operating division of Protide Pharmaceuticals, Inc. providing scientific discovery and innovative cell biology products targeted to measure and interpret the dimensions of biology and medicine. With over twenty-one years of service, in over 35 countries worldwide, our organization continues as an entrepreneurial, science driven organization inspired by the patients, scientists and physicians we support.
Oncosis, Inc. (www.oncosis.com), headquartered in San Diego, CA, is engaged in the design and development of a new generation of medical devices and reagents for cell and gene therapy, using ultra high-speed optical scanning and lasers directed at individual cells. The Company has developed the only technology capable of the efficient removal of contaminating cells and the non-destructive analysis of cell therapy products. The Company's patented Photosis technology is based on scanning cytometry, real-time image analysis, and laser-based treatment of individual cells within a mixed cell population. The Photosis platform can process nearly a half billion cells in less than an hour under sterile conditions, making it useful for cell and gene therapies to treat cancer, cardiovascular, neurological, metabolic and autoimmune diseases.
http://www.nationalstemcell.com
National Stem Cell Holding, Inc. is a biotechnology company emerging from the R&D stage into the commercialization stage and is focused on developing therapeutics based upon the use of human cells and their derivatives.
Chondros, Inc. is a development stage company involved in the discovery, development, and commercialization of novel methodologies, proprietary processing techniques, and clinical applications in the dynamic field of human tissue repair. For the past five years, experimental work at Johns Hopkins University and the Orthopaedic Research laboratories of David Hungerford, MD at Good Samaritan Hospital, in Baltimore, MD has resulted in exciting advancements in techniques of rapid cell proliferation, cell scaffold design, and efficiencies in base cell harvesting. We believe that these advancements have wide ranging applications for defining the next module of progress for the field and that Chondros can enter into strategic collaborations with those companies either already active in the field of human tissue engineering, or with those that might be contemplating entry. Human tissue engineering has opened a new frontier in the development of implant materials for surgery. While the focus of Chondros, Inc. has been on cartilage applications, including orthopaedics, otolaryngology-head and neck surgery, and facial plastic reconstruction, considerable work in liver, pancreas and other regenerative organs is ongoing as well. Bioabsorbable scaffolds, seeded with harvested cells that have been grown ex-vivo can be implanted in the appropriate surgical site to effect defect repair or to create new masses of organ tissues to replace damaged areas. These implants in turn, promote continued tissue regeneration rather than serving as merely inert tissue replacement. The processes involved in harvesting, expanding, and implanting organized cell structures are complicated, and require significant skill expertise and clinical and scientific cooperation. The resources that the Chondros team has assembled represent the leading edge in these fields, and prior to the organization of the company, but in a collaborative mode, have been able to demonstrate quantifiable progress over the current commercial options. It is expected that for the next 2-3 years, the emphasis of Chondros will remain largely technical, aimed at further refinements and expansion of the company's proprietary technologies.
Sertoli Technologies Inc. is a cellular therapy company with platform technology for creating a local immunoprivileged site enabling the therapeutic transplantation of cells and cell-based gene therapy. Sertoli has a comprehensive patent portfolio covering the application of Sertoli cells. Patent applications are filed worldwide in all major markets, including the United States, Europe and Japan. Six U.S. patents have issued containing broad claims that protect the use and application of the Company's technology. The Company is aggressive in the filing of additional patents covering additional therapeutic uses of Sertoli cells and factors derived from Sertoli cells.
Insception Biosciences Inc. is a Canadian company founded by Canadian scientists and physicians. We are the country's largest and most established cord blood bank, and we offer expectant parents the opportunity to store stem cells from the umbilical cord blood which is a valuable alternative to bone marrow. Insception has a strong focus on research and technology development, in addition to its banking services. Our research is focused on developing stem cell-based therapeutic technologies and products to treat a wide range of diseases such as diabetes, MS, stroke and heart disease. Insception Biosciences is an equal opportunity employer. Our state of the art processing laboratory and cryopreservation facility is located in Mississauga, Ontario. Agency referrals will not be accepted. Insception Biosciences' Human Resources must approve all agency referrals. Insception Biosciences will not be responsible for any fees arising from the use of resumes for these job opportunities. If you do not find the opportunity that you are looking for below, feel free to submit a general application to HR@insception.com as an indication of interest in employment with Insception. Your information will remain in our recruitment database for 6 months.
Theregen, Inc. is a cell therapy company that develops cell-based therapies for patients with cardiovascular disease. Theregen has worldwide exclusive rights to research, manufacture, develop and commercialize its lead product, Anginera,, for cardiovascular and vascular applications. The company is conducting two Phase I human clinical safety trials for Anginera, a cell-based epicardial therapy. Anginera has been shown in animal models to have the potential to induce remodeling and angiogenesis in the ischemic heart, leading to functional changes that may benefit patients with heart failure. The company's early-stage financial strategy calls for partnerships with institutional and corporate investors to fund clinical development and provide the resources to research additional product candidates. The company has received equity investments from Sanderling Ventures and Boston Scientific Corporation to help fund clinical development of Anginera. Sanderling continues in 2007 to provide funding necessary to advance the company's clinical programs. Theregen's platform technology also provides attractive product development partnering opportunities. Research into exciting new technologies such as gene therapy and targeted drug delivery has run into serious obstacles. Biotechnology and pharmaceutical companies have begun to recognize the need for living, cell-based, three-dimensional constructs, such as Anginera, as a means of overcoming these barriers and bringing these technologies to fruition.
http://www.morphogenesis-inc.com
Morphogenesis is an emerging cell therapy company developing therapeutic products and devices for the fast-growing, multi-billion dollar cell therapy, tissue engineering and immunotherapy markets. The Company's initiatives can be broken down into three platforms or divisions; Cell Therapy, Immune Therapy and Supporting Technologies. The Problem The continued increase of chronic disease has made it clear that the future of medicine depends on our ability to develop ways to repair, replace or destroy the cells that make up tissue and organ systems which have become defective. The Morphogenesis Solution The Company believes that cells, themselves, represent a more effective mode of treatment than drugs and is developing products which will allow their widespread use as therapeutics. A critical component in any type of cell therapy is the interaction of the therapeutic cell and the immune system of the patient receiving the treatment. Morphogenesis has approached this key issue from both perspectives, i.e., by seeking to evade immune attack where necessary and to harness the immune response when advantageous. For example, replacement cells may come from one's own body, a donor or an animal, but unless the cells come from the patient himself, their use is limited because the transplanted cells will be rejected by the patient's immune system. Morphogenesis' Cell Therapy Division has developed a revolutionary technology which is slated to solve the problem of graft rejection and in turn, address the tissue shortage crisis as well. Alternatively, the Company's Immune Therapy Division is developing ways to use cells in the fight against cancer. Morphogenesis' therapeutic cancer vaccine has already proven efficacyin pre-clinical studies in its ability to focus and target the immune response against cancer cells. The Company's Supporting Technologies Division is actively pursuing ways to identify, isolate and purify stem cells. The vanguard product is a clinical device designed to purify hematopoietic stem cells from peripheral blood. This Division has also developed proprietary methods, cell lines and monoclonal antibodies for the identification of hematopoietic stem cells.
CellExSys, Inc. was established in late 2000 as a subsidiary of Targeted Genetics Corporation, with a focus on commercializing a robust portfolio of cell therapy assets that are outside of Targeted Genetics' core focus. CellExSys' patient-specific technology platform has yielded promising results in preclinical studies of a variety of viral diseases and cancers.
Islet Technology, Inc. (ITI) is a biomedical company focused on the processing and purification of insulin-producing islets to be supplied to transplant centers, eventually worldwide. Our core technologies are islet isolation and encapsulation. We are committed to seeing a cure for diabetes happen in our lifetimes. ITI has developed a valuable intellectual property portfolio covering both islet isolation and encapsulation, which we believe will provide the protection needed to effectively commercialize our islet processing services. Islet transplantation is currently in the final phase of human clinical trials begun in the year 2000. For the majority of participants in the trials, the need for externally administered insulin has either been eliminated or greatly reduced, making them insulin self-sufficient. In 2004, it is expected that data from these trials will be submitted to the FDA for approval in order to begin the process of making islet transplants more broadly available. In preparation for commercialization, ITI is in the process of establishing an islet processing center in the Minneapolis/St. Paul area of Minnesota. Once this facility is approved, ITI will be able to supply islets to transplant centers in the U.S. Much work needs to be done in many areas to ensure the availability of islet transplants. Fortunately on the reimbursement front, the recently-passed Medicare Prescription Drug Act established an important precedent by covering islet transplants within clinical trials involving Medicare patients with end stage renal disease. Private insurance companies look to Medicare for leadership in defining new treatments to be covered, so this Medicare study is an important milestone. Islet transplantation will grow as the source of islets expands. ITI expects that islet supply will progress from the current limited supply of deceased donors to include living donors (of partial pancreata), and eventually islets harvested from pigs - a virtually unlimited source. ITI's processing facilities will be able to handle the isolation of islets from all of these sources. When ITI's encapsulation technology is introduced in clinical trials, islets will also be encapsulated at ITI's processing center. Encapsulation involves coating islets with Algi-pure, our proprietary biocompatible material designed to protect islets from attack by the body's immune system. Encapsulation is expected to eliminate or greatly reduce the need for the transplant recipient to take immunosuppressive drugs.
AmCyte's proprietary encapsulation technology is based on a novel alginate polymer and poly-L-lysine membrane configuration, in which the cells are encased in immunoprotective capsules. Protected by 16 issued patents, the technology has been refined by extensive know-how in material selection and process optimisation. The capsule system allows small molecules and peptides produced by the encapsulated cells to transfer out of the capsule; allows nutrients to pass through the capsule to reach the cells; preserves cell function; is formulated to be biocompatible without immune suppression of the patient, and can be transplanted under a straightforward surgical procedure and be readily retrieved.
Located in Irvine, California, Nexell Therapeutics Inc. (Nasdaq:NEXL) is a cell therapy company whose mission is to put the healing power of the cell into the hands of physicians. Nexell is developing and marketing innovative ex vivo cell therapies and in vitro diagnostics for cancer, autoimmune, metabolic and genetic diseases. Nexell's lead product, the Isolex® 300i Magnetic Cell Selection System, is the only FDA approved device commercially available for the selection of hematopoietic stem cells and the removal of tumor cells from autologous peripheral blood as a component of aggressive cancer treatment. In addition, Nexell markets the Cytonex ICC Staining Kit and an extensive line of cell therapy preparation, storage and expansion products including the Cryocyte, SteriCell® and Lifecell® brands.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory